Olstykke, Denmark and Martigny, Switzerland – May 29, 2026 – Minerva Imaging, a market-leading, integrated Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CDMO) specialized in targeted radioligand therapies, today announced a strategic collaboration with Debiopharm, a Swiss-based biopharmaceutical company focused on the development of innovative therapies in oncology and infectious diseases.

The collaboration centers around the integration of Debiopharm’s proprietary AbYlink™ conjugation technology into Minerva Imaging’s preclinical research platform, supporting the development of next-generation radiopharmaceuticals as well as other targeted conjugates. AbYlink™ enables one step regio-selective conjugation of a variety of payloads on the Fc domain of antibodies without affecting antigen-binding domains. Under the license agreement, Minerva Imaging will apply the technology to the development of theranostics, and emerging biologic-based radiopharmaceutical formats.

For Minerva Imaging’s customers, the addition of AbYlink™ expands the toolbox available for designing more precise and better-characterized targeted agents. The technology can support evaluation of biological vectors such as antibodies, antibody drug conjugates, antibody fragments, and other Fc-containing molecules for delivery of radioisotopes or other payloads, while preserving target binding and enabling more controlled construct design during discovery and translational development.

The collaboration also reflects a broader evolution in radiopharmaceutical development, as the field expands beyond small molecules and peptides towards more complex biological vectors that may offer differentiated targeting, pharmacokinetics, and payload flexibility. By incorporating AbYlink™ into its integrated platform, Minerva Imaging is positioned to support customers developing these next-generation approaches from early concept evaluation through translational studies and manufacturing readiness.

“Radiopharmaceuticals are rapidly transforming oncology, and at Minerva Imaging we are at the forefront of the developments.” said Carsten H. Nielsen, CEO and Co-founder of Minerva Imaging. “With the integration of AbYlink™ into our capabilities, we further strengthen our fully integrated radiopharmaceutical platform. Importantly, this gives our customers new opportunities to evaluate biologically derived targeting vectors and develop more advanced, precisely engineered radiopharmaceuticals and conjugates across the drug development pathway.”

“Debiopharm is pleased to collaborate with Minerva Imaging to broaden the application of AbYlink™ in targeted therapeutic development,” said Frederic Levy, Chief Scientific Officer, Debiopharm. “By combining Debiopharm’s conjugation technology with Minerva Imaging’s radiopharmaceutical research and development capabilities, this collaboration has the potential to accelerate innovation in next-generation targeted therapies.”

About Minerva Imaging
Minerva Imaging is a fully integrated CRO and CDMO specialized in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services. Minerva’s competences are built on over 25 years of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark. Follow Minerva Imaging on LinkedIn for the latest news updates or visit www.minervaimaging.com for more information.

About Debiopharm
Debiopharm is a privately owned, Swiss-based biopharmaceutical company with the ambition to develop therapies that cure cancer and infectious diseases. We identify high-potential compounds and technologies for in licensing, drive programs through translational medicine and clinical development milestones, to then and then select international pharmaceutical partners for commercialization. Through collaboration with other radioligand therapy expert organisations, we seek to accelerate innovation that helps patients live longer.

For more information: www.debiopharm.com/our-expertise/radioligand-therapy/
or follow us: www.linkedin.com/company/debiopharminternational/

About AbYlink™
AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use in preparing diagnostic or therapeutic conjugates. This one step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads.

AbYlink is a registered trademark of Debiopharm International SA

Media Contacts:

Fabian Pruissen
Senior Business Developer
BD@minervaimaging.com

Dawn Bonine
Head of Communications
dawn.bonine@debiopharm.com